Welcome to our dedicated page for Adapthealth news (Ticker: AHCO), a resource for investors and traders seeking the latest updates and insights on Adapthealth stock.
AdaptHealth Corp (AHCO) delivers essential home medical equipment and healthcare-at-home services, empowering patients through respiratory care, mobility solutions, and chronic condition management. This page provides centralized access to all official company announcements and market-relevant developments.
Investors and healthcare professionals will find timely updates on earnings reports, regulatory milestones, product launches, and strategic partnerships. Our curated collection includes press releases on sleep therapy innovations, respiratory equipment advancements, and operational expansions across AHCO's nationwide network.
Key areas covered include quarterly financial results, clinical service enhancements, Medicare/Medicaid compliance updates, and technology integrations in home healthcare. All content is sourced directly from AdaptHealth's communications to ensure accuracy and relevance for stakeholders.
Bookmark this page for streamlined access to AHCO's latest business developments. Check regularly for updates impacting the home healthcare sector and AdaptHealth's position within this critical industry.
AdaptHealth Corp. (NASDAQ: AHCO) announced that its CEO Steve Griggs, President Josh Parnes, and CFO Jason Clemens will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17 at 1:20 pm ET. A live webcast will be available through the Investors section of AdaptHealth’s website. The company is a leader in providing patient-centered, healthcare-at-home solutions, serving approximately 3.5 million patients annually across 716 locations in 47 states with a full suite of medical products.
AdaptHealth Corp. (NASDAQ: AHCO) reported a record net revenue of $653.3 million for Q3 2021, a 130% increase from the previous year, alongside a net income of $58.1 million, reversing a $51 million loss. Adjusted EBITDA surged 194% to $156.3 million. The company completed six acquisitions and has increased its fiscal 2021 revenue guidance to $2.41-$2.46 billion. For 2022, guidance is set at $2.70-$2.90 billion in revenue. Management is confident in driving organic growth through strategic acquisitions despite market challenges.
AdaptHealth Corp. (NASDAQ: AHCO) is set to release its third quarter 2021 financial results before the market opens on
AdaptHealth Corp. (NASDAQ: AHCO) has announced the appointment of Greg Belinfanti to its Board of Directors, representing One Equity Partners. Belinfanti brings extensive board experience, having served on various healthcare-related boards, including Arthrocare (NASDAQ: ARTC). Brad Coppens, the previous OEP designee, will remain an independent director. Chairman Richard Barasch expressed appreciation for OEP's support and welcomed Belinfanti's expertise, which aims to strengthen the board's leadership and strategic direction.
AdaptHealth Corp. (NASDAQ: AHCO) has announced a successful pricing of $600 million in 5.125% senior notes due 2030, increasing from a previously planned $550 million. The offering is aimed at qualified institutional buyers and is expected to close on August 19, 2021. Proceeds will be used to repay existing promissory notes, pay off revolving credit, cover related fees, and for general corporate needs, including acquisitions. The notes will be guaranteed by certain subsidiaries and the Issuer’s parent company.
AdaptHealth Corp. (NASDAQ: AHCO) announced the commencement of a $550 million offering of senior notes due 2030 through its subsidiary, AdaptHealth LLC. These senior notes will be guaranteed by certain subsidiaries and the parent company on a senior unsecured basis. The net proceeds will be used to repay outstanding debt, including 12% promissory notes and amounts under its revolving credit facility, as well as for general corporate purposes. The offering is targeted at qualified institutional buyers and is not registered under the Securities Act.
AdaptHealth Corp. (NASDAQ: AHCO) has appointed Anton Hie as the new Vice President of Investor Relations. This newly created position will see Mr. Hie working closely with senior management to enhance the company's growth and competitive strategy, managing communications with shareholders and the investment community. With 20 years of experience in healthcare investment, including 12 years at RBC Capital Markets, Hie brings substantial expertise to the team. AdaptHealth serves approximately 3.3 million patients annually across 678 locations in 47 states.
AdaptHealth Corp. (NASDAQ: AHCO) reported record financial results for Q2 2021, achieving net revenue of $617.0 million, a 166% increase from Q2 2020. The company also saw a net income of $79.1 million ($0.12 per diluted share), up from $4.5 million. Adjusted EBITDA rose by 246% to $147.4 million. AdaptHealth completed four acquisitions during the quarter, contributing to significant organic growth of 10.1%. The company has increased its 2021 guidance, now expecting net revenue between $2.38 and $2.48 billion.
AdaptHealth Corp. (NASDAQ: AHCO) will release its Q2 2021 financial results on August 5, 2021, prior to market opening. A conference call will follow at 8:30 AM ET to discuss the results and business updates. AdaptHealth is a leading provider of at-home healthcare solutions, serving nearly 3 million patients annually across over 500 locations in 47 states. The company offers a range of products including sleep therapy, diabetes care devices, and home medical equipment, focusing on chronic condition management.
AdaptHealth Corp. (NASDAQ: AHCO) has appointed Stephen Griggs as Chief Executive Officer, effective immediately, following Luke McGee's resignation from the same position. Griggs, who joined AdaptHealth in February 2021 as Co-CEO, has a strong track record in the healthcare sector, having founded AeroCare and achieved two decades of consecutive revenue growth. The board expresses confidence in Griggs’ leadership as the company aims to enhance organic growth, improve chronic disease management, and pursue strategic acquisitions.